The risk for cardiovascular events associated with systemic therapies for psoriasis, including biologics, is unclear.
Methods
We used administrative data from Medicare 2006 through 2011 to identify psoriasis patients who initiated systemic treatments. We estimated incidence rates of hospitalized myocardial infarction, stroke, and a composite cardiovascular disease outcome, adjusting for potentially confounding factors.
Results
There were 28,878 initiations of psoriasis treatments. Rates of myocardial infarction were highest for methotrexate (10.32/1000 patient-years, 95%CI 8.55–12.46) and numerically lower for biologics. Patterns were similar for stroke and the composite cardiovascular disease outcome. After multivariable adjustment, there were no significant differences between systemic therapies for any of the outcomes studied.
Conclusions
In this cohort of predominantly older psoriasis patients, there was neither an elevated nor a protective effect on cardiovascular or stroke events associated with systemic therapies for psoriasis compared to conventional treatments.
AhlehoffO., SkovL., GislasonG.. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.J Intern Med.2013; 273(2): 197–204.
2.
AlamdariH.S., GustafsonC.J., DavisS.A., HuangW., FeldmanS.R.. Psoriasis and cardiovascular screening rates in the United States.J Drugs Dermatol.2013; 12(1): e14–9.
CalamitaA.B., CalamitaZ., BragaJ.C.. Risk factors for cardiovascular disease in psoriasis: relation to inflammation assessed by the severity and duration of illness.Inflamm Allergy Drug Targets.2013; 12(6): 385–90.
5.
ChenY-J, ChangY-T, ShenJ-L. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: A nationwide cohort study.Arthritis Rheum.2012; 64(6): 1879–87.
6.
CostaL., CasoF., AttenoM.. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.Clin Rheumatol.2014; 33(6): 833–9.
7.
DavidoviciB.B., SattarN., PrinzJ.. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions.J Invest Dermatol.2010; 130(7): 1785–96.
8.
EderL., ThavaneswaranA., ChandranV., CookR., GladmanD.D.. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis.Ann Rheum Dis.2015; 74(10): 1830–5.
GelfandJ.M., NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B.. Risk of myocardial infarction in patients with psoriasis.JAMA.2006; 296(14): 1735–41.
11.
GelfandJ.M., TroxelA.B., LewisJ.D.. The risk of mortality in patients with psoriasis: results from a population-based study.Arch Dermatol.2007; 143(12): 1493–9.
12.
HerrintonL.J., CurtisJ.R., ChenL.. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.Pharmacoepidemiol Drug Saf.2011; 20(11): 1199–209.
13.
HerronM.D., HinckleyM., HoffmanM.S.. Impact of obesity and smoking on psoriasis presentation and management.Arch Dermatol.2005; 141(12): 1527–34.
14.
HorreauC., PouplardC., BrenautE.. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.J Eur Acad Dermatol Venereol.2013; 27 Suppl 3: 12–29.
15.
HughJ., Van VoorheesA.S., NijhawanR.I.. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.J Am Acad Dermatol.2014; 70(1): 168–77.
16.
KimballA.B., GladmanD., GelfandJ.M.. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.J Am Acad Dermatol.2008; 58(6): 1031–42.
17.
LanC.C., KoY.C., YuH.S.. Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study.Acta Derm Venereol.2012; 92(4): 349–52.
18.
LoveT.J., QureshiA.A., KarlsonE.W., GelfandJ.M., ChoiH.K.. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006.Arch Dermatol.2011; 147(4): 419–24.
19.
MaC., HarskampC.T., ArmstrongE.J., ArmstrongA.W.. The association between psoriasis and dyslipidaemia: a systematic review.Br J Dermatol.2013; 168(3): 486–95.
20.
ParsiK.K., BrezinskiE.A., LinT.C., LiC.S., ArmstrongA.W.. Are patients with psoriasis being screened for cardiovascular risk factors?A study of screening practices and awareness among primary care physicians and cardiologists. J Am Acad Dermatol.2012; 67(3): 357–62.
21.
CutronaS.L., TohS., IyerA.. Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program.Pharmacoepidemiol Drug Saf.2013; 22(1): 40–54.
22.
KiyotaY., SchneeweissS., GlynnR.J., CannuscioC.C., AvornJ., SolomonD.H.. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.Am Heart J.2004; 148(1): 99–104.
23.
Birman-DeychE., WatermanA.D., YanY., NilasenaD.S., RadfordM.J., GageB.F.. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors.Med Care.2005; 43(5): 480–5.
RoumieC.L., MitchelE., GideonP.S., Varas-LorenzoC., CastellsagueJ., GriffinM.R.. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.Pharmacoepidemiol Drug Saf.2008; 17(1): 20–6.
26.
TirschwellD.L., LongstrethW.T.Jr.. Validating administrative data in stroke research.Stroke.2002; 33(10): 2465–70.
27.
CharlsonM.E., PompeiP., AlesK.L., MacKenzieC.R.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chronic Dis.1987; 40(5): 373–83.
28.
BraitmanL.E., RosenbaumP.R.. Rare outcomes, common treatments: analytic strategies using propensity scores.Ann Intern Med.2002; 137(8): 693–5.
29.
D'AgostinoR.B.Jr.. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.Stat Med.1998; 17(19): 2265–81.
30.
PhamH.H., SchragD., HargravesJ.L., BachP.B.. Delivery of preventive services to older adults by primary care physicians.JAMA.2005; 294(4): 473–81.
31.
WhiteH.. A heteroskedasticity-consistent covariace matrix estimator and a direct test for heteroscedasticity.Econometrica1980; 48: 817–30.
32.
PinaT., ArmestoS., Lopez-MejiasR.. Anti-TNF-alpha therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.J Eur Acad Dermatol Venereol.2015; 29(7): 1325–30.
33.
ProdanovichS., MaF., TaylorJ.R., PezonC., FasihiT., KirsnerR.S.. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.J Am Acad Dermatol.2005; 52(2): 262–7.
34.
QureshiA.A., ChoiH.K., SettyA.R., CurhanG.C.. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses.Arch Dermatol.2009; 145(4): 379–82.
35.
RappS.R., FeldmanS.R., ExumM.L., FleischerA.B.Jr., ReboussinD.M.. Psoriasis causes as much disability as other major medical diseases.J Am Acad Dermatol.1999; 41(3 Pt 1): 401–7.
36.
RosenC.F., MussaniF., ChandranV., EderL., ThavaneswaranA., GladmanD.D.. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology.(Oxford, England)2012; 51(3): 571–6.
37.
RoubilleC., RicherV., StarninoT.. Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.J Rheumatol.2015 Oct; 42(10): 1767–80.
38.
SolomonD.H., LoveT.J., CanningC., SchneeweissS.. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis.Ann Rheum Dis.2010; 69(12): 2114–7.
39.
VirnigG M.A.. Strengths and Limitations of CMS Administrative Data in Research 8/28/12, 2012. http://www.resdac.org (accessed 3/16/15).
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
